chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 22.0
Sex: F
Vaccine: COVID19, FLU4
Symptoms: Dizziness, Syncope
Clinical narrative: Patient had 1 vaccine for Spikevax on her left arm and then experienced syncope for approximately 5 seconds after her second vaccine (Fluzone Quad) on her right arm. She remained in her seat, didn't injure herself and initially felt light headed.  She also vomited and stated that previously had history of syncope due to menstrual cramps which she is currently on day 3 of. She recovered, had no further symptoms, and able to leave after 15 minutes.
Age: 32.0
Sex: F
Vaccine: RSV
Symptoms: Brain fog, Exposure during pregnancy, Fatigue, Nausea, Pain
Clinical narrative: G4P1021, Current pregnancy due date 3/2/24, current weight of patient 204 lbs. Patient reports nausea, generalized body aches, and increased fatigue, brain fog, runny nose.
Age: 32.0
Sex: F
Vaccine: RSV
Symptoms: Rhinorrhoea
Clinical narrative: G4P1021, Current pregnancy due date 3/2/24, current weight of patient 204 lbs. Patient reports nausea, generalized body aches, and increased fatigue, brain fog, runny nose.
Age: 74.0
Sex: F
Vaccine: VARZOS
Symptoms: Product storage error
Clinical narrative: Vaccine frozen instead of refrigerated
Age: 74.0
Sex: F
Vaccine: VARZOS
Symptoms: Product storage error
Clinical narrative: Vaccine was frozen instead of refrigerated
Age: 4.0
Sex: F
Vaccine: DTAPIPV
Symptoms: Erythema, Skin warm
Clinical narrative: REDNESS, HOT BY TOUCH
Age: 57.0
Sex: F
Vaccine: VARZOS
Symptoms: Product storage error
Clinical narrative: VACCINE FROZEN INSTEAD OF VACCINATED
Sex: U
Vaccine: COVID19
Symptoms: Arthralgia, Fatigue, Myalgia, Vaccination site pain
Clinical narrative: Joint pain and no interference with activity; Mild muscle pain and no interference with activity; Mild fatigue and no interference with activity; Mild injection site pain and no interference with activity; This spontaneous case was reported by a non-health professional and describes the occurrence of ARTHRALGIA (Joint pain and no interference with activity), MYALGIA (Mild muscle pain and no interference with activity), FATIGUE (Mild fatigue and no interference with activity) and VACCINATION SITE PAIN (Mild injection site pain and no interference with activity) in a patient of an unknown age and gender who received mRNA-1273.815 (SPIKEVAX 2023-2024) for COVID-19 prophylaxis.     No Medical History information was reported.    In December 2023, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form. In December 2023, the patient experienced ARTHRALGIA (Joint pain and no interference with activity), MYALGIA (Mild muscle pain and no interference with activity), FATIGUE (Mild fatigue and no interference with activity) and VACCINATION SITE PAIN (Mild injection site pain and no interference with activity). At the time of the report, ARTHRALGIA (Joint pain and no interference with activity), MYALGIA (Mild muscle pain and no interference with activity), FATIGUE (Mild fatigue and no interference with activity) and VACCINATION SITE PAIN (Mild injection site pain and no interference with activity) outcome was unknown.        The action taken with mRNA-1273.815 (SPIKEVAX 2023-2024) (Unknown) was unknown.       Concomitant medication was not provided. The patient experienced events anytime during the 2 days after COVID-19 vaccination, which occurred on 23-Dec-2023 and 24-Dec-2023. Treatment information was not reported.   This case was linked to US-MODERNATX, INC.-MOD-2024-755971 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2024-755971:Same reporter
Age: 53.0
Sex: M
Vaccine: VARZOS
Symptoms: Product storage error
Clinical narrative: Vaccine was frozen instead of refrigerated
Age: 71.0
Sex: F
Vaccine: VARZOS
Symptoms: Headache, Pain
Clinical narrative: Body aches. Moderate to severe headache started about 12 hours after vaccination and contines 18 hours after vaccination. Ibuprophen provides littles relief.
Age: 60.0
Sex: F
Vaccine: VARZOS
Symptoms: Product storage error
Clinical narrative: Vaccine was frozen instead of refrigerated
Age: 17.0
Sex: M
Vaccine: COVID19-2, MENB
Symptoms: Chest pain
Clinical narrative: Chest pain
Age: 31.0
Sex: F
Vaccine: HEP
Symptoms: Dizziness, Flushing, Nausea, Vomiting
Clinical narrative: flushed, dizzy. naseous, vomiting
Age: 40.0
Sex: F
Vaccine: FLUC4, TDAP
Symptoms: Immediate post-injection reaction, Mobility decreased, Nerve injury, Pain, Pain in extremity
Clinical narrative: Immediately After injection my left arm started hurting, the tech said it would go away in a couple of days, when it didn't get better I went to the urgent care on 11-27-23 and saw NP. We discussed SIRVA and referred to physical therapy. Also saw PCP on12-27-23 who also agreed its SIRVA nerve damage.  Pain and loss of motion due to pain.
Age: 40.0
Sex: F
Vaccine: FLUC4, TDAP
Symptoms: Shoulder injury related to vaccine administration
Clinical narrative: Immediately After injection my left arm started hurting, the tech said it would go away in a couple of days, when it didn't get better I went to the urgent care on 11-27-23 and saw NP. We discussed SIRVA and referred to physical therapy. Also saw PCP on12-27-23 who also agreed its SIRVA nerve damage.  Pain and loss of motion due to pain.
Age: 80.0
Sex: M
Vaccine: FLUA4, UNK
Symptoms: Dizziness, Malaise, Syncope
Clinical narrative: patient received two vaccines, Flu and Arexvy. After receiving the vaccine ( per pt in couple hours) he started experiencing diziness, fainting and was not feeling well and was taken to the hospital. spoke with patient on 01/11/2024 , per patient he was doing much better but he is still in the hospital.
Age: 33.0
Sex: F
Vaccine: FLUA4
Symptoms: Pain, Pain in extremity
Clinical narrative: Got flu vaccine 11/30/2023. States one week after injection she had arm pain. She has been using Ibuprofen, arm exercises and salt baths to help with pain. She has tried ice to the region without changes. The pain comes and goes. Worse when lifting. No skin or color changes to the region.
Age: 17.0
Sex: M
Vaccine: MENB
Symptoms: Chest X-ray normal, Influenza virus test negative, Pyrexia, Respiratory syncytial virus test negative, SARS-CoV-2 test negative
Clinical narrative: Vomiting that was nonstop until noon the next day that was remedied with IV fluids and Iv Zofran in Emergency Department. Low-grade fever that resolved within 24 hours without medication.
Age: 17.0
Sex: M
Vaccine: MENB
Symptoms: Streptococcus test negative, Vomiting
Clinical narrative: Vomiting that was nonstop until noon the next day that was remedied with IV fluids and Iv Zofran in Emergency Department. Low-grade fever that resolved within 24 hours without medication.
Age: 40.0
Sex: F
Vaccine: HEP
Symptoms: Body temperature increased, Chest discomfort, Dizziness, Dyspnoea, Headache
Clinical narrative: About 4 hours after receiving the vaccine, the recipient started to feel to feel shortness of breath, tightness in her chest, headache, dizziness, nausea, warmth and swelling on injection site, and a temperature of 101 Fahrenheit. Recipient stated she took Tylenol, Advil, Albuterol,  and also applied an ice pack to her arm due to the swelling. Recipient states that she still feels some chest tightness and it is difficult to take a deep breath.
Age: 40.0
Sex: F
Vaccine: HEP
Symptoms: Injection site swelling, Injection site warmth, Nausea
Clinical narrative: About 4 hours after receiving the vaccine, the recipient started to feel to feel shortness of breath, tightness in her chest, headache, dizziness, nausea, warmth and swelling on injection site, and a temperature of 101 Fahrenheit. Recipient stated she took Tylenol, Advil, Albuterol,  and also applied an ice pack to her arm due to the swelling. Recipient states that she still feels some chest tightness and it is difficult to take a deep breath.
Age: 66.0
Sex: M
Vaccine: RSV, RSV
Symptoms: Electromyogram, Guillain-Barre syndrome, Lumbar puncture
Clinical narrative: GBS - Guillain-Barre Syndrome -
Sex: U
Vaccine: COVID19
Symptoms: Arthralgia, Body temperature, Fatigue, Headache, Malaise
Clinical narrative: Moderate malaise/feeling sick present with some interference with activity; Severe fatigue with significant interference with activity; Joint pain and no interference with activity; Moderate muscle pain with some interference with activity; Significant fever (> 102 °F); Headache and no interference with activity; Mild injection site redness; This spontaneous case was reported by a non-health professional and describes the occurrence of MALAISE (Moderate malaise/feeling sick present with some interference with activity), FATIGUE (Severe fatigue with significant interference with activity), ARTHRALGIA (Joint pain and no interference with activity), MYALGIA (Moderate muscle pain with some interference with activity) and PYREXIA (Significant fever (> 102 °F)) in a patient of an unknown age and gender who received mRNA-1273.815 (SPIKEVAX 2023-2024) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    In December 2023, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form. In December 2023, the patient experienced MALAISE (Moderate malaise/feeling sick present with some interference with activity), FATIGUE (Severe fatigue with significant interference with activity), ARTHRALGIA (Joint pain and no interference with activity), MYALGIA (Moderate muscle pain with some interference with activity), PYREXIA (Significant fever (> 102 °F)), HEADACHE (Headache and no interference with activity) and VACCINATION SITE ERYTHEMA (Mild injection site redness). At the time of the report, MALAISE (Moderate malaise/feeling sick present with some interference with activity), FATIGUE (Severe fatigue with significant interference with activity), ARTHRALGIA (Joint pain and no interference with activity), MYALGIA (Moderate muscle pain with some interference with activity), PYREXIA (Significant fever (> 102 °F)), HEADACHE (Headache and no interference with activity) and VACCINATION SITE ERYTHEMA (Mild injection site redness) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In December 2023, Body temperature: Greater than 102 °F.     The action taken with mRNA-1273.815 (SPIKEVAX 2023-2024) (Unknown) was unknown.       Concomitant medication was not provided.  It was reported that the patient experienced the events anytime during the 2 days after the COVID-19 vaccination, which occurred Saturday, Dec 23, 2023 and Sunday, Dec 24, 2023.  Treatment information was not reported.   This case was linked to US-MODERNATX, INC.-MOD-2024-755971 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2024-755971:same reporter
Sex: U
Vaccine: COVID19
Symptoms: Myalgia, Pyrexia, Vaccination site erythema
Clinical narrative: Moderate malaise/feeling sick present with some interference with activity; Severe fatigue with significant interference with activity; Joint pain and no interference with activity; Moderate muscle pain with some interference with activity; Significant fever (> 102 °F); Headache and no interference with activity; Mild injection site redness; This spontaneous case was reported by a non-health professional and describes the occurrence of MALAISE (Moderate malaise/feeling sick present with some interference with activity), FATIGUE (Severe fatigue with significant interference with activity), ARTHRALGIA (Joint pain and no interference with activity), MYALGIA (Moderate muscle pain with some interference with activity) and PYREXIA (Significant fever (> 102 °F)) in a patient of an unknown age and gender who received mRNA-1273.815 (SPIKEVAX 2023-2024) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    In December 2023, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form. In December 2023, the patient experienced MALAISE (Moderate malaise/feeling sick present with some interference with activity), FATIGUE (Severe fatigue with significant interference with activity), ARTHRALGIA (Joint pain and no interference with activity), MYALGIA (Moderate muscle pain with some interference with activity), PYREXIA (Significant fever (> 102 °F)), HEADACHE (Headache and no interference with activity) and VACCINATION SITE ERYTHEMA (Mild injection site redness). At the time of the report, MALAISE (Moderate malaise/feeling sick present with some interference with activity), FATIGUE (Severe fatigue with significant interference with activity), ARTHRALGIA (Joint pain and no interference with activity), MYALGIA (Moderate muscle pain with some interference with activity), PYREXIA (Significant fever (> 102 °F)), HEADACHE (Headache and no interference with activity) and VACCINATION SITE ERYTHEMA (Mild injection site redness) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In December 2023, Body temperature: Greater than 102 °F.     The action taken with mRNA-1273.815 (SPIKEVAX 2023-2024) (Unknown) was unknown.       Concomitant medication was not provided.  It was reported that the patient experienced the events anytime during the 2 days after the COVID-19 vaccination, which occurred Saturday, Dec 23, 2023 and Sunday, Dec 24, 2023.  Treatment information was not reported.   This case was linked to US-MODERNATX, INC.-MOD-2024-755971 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2024-755971:same reporter
Sex: U
Vaccine: COVID19
Symptoms: Vaccination site pain, Vomiting
Clinical narrative: Mild malaise/feeling sick and no interference with activity; Moderate fatigue with some interference with activity; Mild muscle pain and no interference with activity; Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting; Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting; Mild injection site pain and no interference with activity/Moderate injection site tenderness (tenderness with movement); Mild injection site redness; This spontaneous case was reported by a non-health professional and describes the occurrence of MALAISE (Mild malaise/feeling sick and no interference with activity), FATIGUE (Moderate fatigue with some interference with activity), MYALGIA (Mild muscle pain and no interference with activity), NAUSEA (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting) and VOMITING (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting) in a patient of an unknown age and gender who received mRNA-1273.815 (SPIKEVAX 2023-2024) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    In December 2023, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form. In December 2023, the patient experienced MALAISE (Mild malaise/feeling sick and no interference with activity), FATIGUE (Moderate fatigue with some interference with activity), MYALGIA (Mild muscle pain and no interference with activity), NAUSEA (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting), VOMITING (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting), VACCINATION SITE PAIN (Mild injection site pain and no interference with activity/Moderate injection site tenderness (tenderness with movement)) and VACCINATION SITE ERYTHEMA (Mild injection site redness). At the time of the report, MALAISE (Mild malaise/feeling sick and no interference with activity), FATIGUE (Moderate fatigue with some interference with activity), MYALGIA (Mild muscle pain and no interference with activity), NAUSEA (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting), VOMITING (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting), VACCINATION SITE PAIN (Mild injection site pain and no interference with activity/Moderate injection site tenderness (tenderness with movement)) and VACCINATION SITE ERYTHEMA (Mild injection site redness) outcome was unknown.        The action taken with mRNA-1273.815 (SPIKEVAX 2023-2024) (Unknown) was unknown.       Concomitant medication was not provided. The patient experienced events anytime during the 2 days after COVID-19 vaccination, which occurred on 24-Dec-2023 and 25-Dec-2023. Treatment information was not reported.   This case was linked to US-MODERNATX, INC.-MOD-2024-755971 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2024-755971:Same reporter
Sex: U
Vaccine: COVID19
Symptoms: Fatigue, Headache, Nausea, Vaccination site pain, Vomiting
Clinical narrative: Mild injection site pain and no interference with activity/Mild injection site tenderness (tender to touch); Mild fatigue and no interference with activity; Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting; Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting; Headache and no interference with activity; This spontaneous case was reported by a non-healthcare professional and describes the occurrence of VACCINATION SITE PAIN (Mild injection site pain and no interference with activity/Mild injection site tenderness (tender to touch)), FATIGUE (Mild fatigue and no interference with activity), NAUSEA (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting), VOMITING (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting) and HEADACHE (Headache and no interference with activity) in a patient of an unknown age and gender who received mRNA-1273.815 (SPIKEVAX 2023-2024) for COVID-19 prophylaxis.     No Medical History information was reported.    In December 2023, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form. In December 2023, the patient experienced VACCINATION SITE PAIN (Mild injection site pain and no interference with activity/Mild injection site tenderness (tender to touch)), FATIGUE (Mild fatigue and no interference with activity), NAUSEA (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting), VOMITING (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting) and HEADACHE (Headache and no interference with activity). At the time of the report, VACCINATION SITE PAIN (Mild injection site pain and no interference with activity/Mild injection site tenderness (tender to touch)), FATIGUE (Mild fatigue and no interference with activity), NAUSEA (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting), VOMITING (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting) and HEADACHE (Headache and no interference with activity) outcome was unknown.            No concomitant medications were reported. All event  which occurred on Saturday, Dec 23, 2023 and Sunday, Dec 24, 2023. No treatment medications were reported.   This case was linked to US-MODERNATX, INC.-MOD-2024-755971 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2024-755971:Same reporter
Sex: U
Vaccine: COVID19
Symptoms: Body temperature, Injection site pain
Clinical narrative: Mild injection site pain and no interference with activity; This spontaneous case was reported by a consumer and describes the occurrence of INJECTION SITE PAIN (Mild injection site pain and no interference with activity) in a  patient of an unknown age and gender who received mRNA-1273.815 (SPIKEVAX 2023-2024) for COVID-19 prophylaxis.     No Medical History information was reported.    In December 2023, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form. In December 2023, the patient experienced INJECTION SITE PAIN (Mild injection site pain and no interference with activity). At the time of the report, INJECTION SITE PAIN (Mild injection site pain and no interference with activity) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Body temperature: No fever (less than 100.4 degree F).     The action taken with mRNA-1273.815 (SPIKEVAX 2023-2024) (Unknown) was unknown.       The Subject ID was reported as: 69969-91898. The Subject ID was reported as: 5471571. No concomitant medications were reported. It was reported that patient experienced mild injection site pain and no interference with activity anytime during the 2 days after your COVID-19 vaccination which occurred on Tuesday, 19-Dec-2023 and Wednesday, 20-Dec-2023 No treatment medications were reported.   This case was linked to US-MODERNATX, INC.-MOD-2024-756099 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2024-756099:
Sex: U
Vaccine: COVID19
Symptoms: Body temperature, Malaise, Myalgia, Vaccination site pain
Clinical narrative: Mild malaise/feeling sick and no interference with activity; Moderate injection site pain interfering with activity/Mild injection site tenderness (tender to touch); Mild muscle pain and no interference with activity; This spontaneous case was reported by a non-health professional and describes the occurrence of MALAISE (Mild malaise/feeling sick and no interference with activity), VACCINATION SITE PAIN (Moderate injection site pain interfering with activity/Mild injection site tenderness (tender to touch)) and MYALGIA (Mild muscle pain and no interference with activity) in a patient of an unknown age and gender who received mRNA-1273.815 (SPIKEVAX 2023-2024) for COVID-19 prophylaxis.     No Medical History information was reported.    In December 2023, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form. In December 2023, the patient experienced MALAISE (Mild malaise/feeling sick and no interference with activity), VACCINATION SITE PAIN (Moderate injection site pain interfering with activity/Mild injection site tenderness (tender to touch)) and MYALGIA (Mild muscle pain and no interference with activity). At the time of the report, MALAISE (Mild malaise/feeling sick and no interference with activity), VACCINATION SITE PAIN (Moderate injection site pain interfering with activity/Mild injection site tenderness (tender to touch)) and MYALGIA (Mild muscle pain and no interference with activity) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In December 2023, Body temperature: less than 100.4 degree Fahrenheit.     The action taken with mRNA-1273.815 (SPIKEVAX 2023-2024) (Unknown) was unknown.       No concomitant medication was reported.  Patient had experienced events anytime during the 2 days after your COVID-19 vaccination, which occurred on Saturday, Dec 23, 2023, and Sunday, Dec 24, 2023.  No treatment information was reported.   This case was linked to US-MODERNATX, INC.-MOD-2024-756004 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2024-756004:Same reporter
Sex: U
Vaccine: COVID19
Symptoms: Fatigue, Malaise, Vaccination site erythema, Vaccination site pain
Clinical narrative: Mild malaise/feeling sick and no interference with activity; Moderate injection site pain interfering with activity/Moderate injection site tenderness (tenderness with movement); Mild injection site redness; Mild fatigue and no interference with activity; This spontaneous case was reported by a non-health professional and describes the occurrence of MALAISE (Mild malaise/feeling sick and no interference with activity), VACCINATION SITE PAIN (Moderate injection site pain interfering with activity/Moderate injection site tenderness (tenderness with movement)), VACCINATION SITE ERYTHEMA (Mild injection site redness) and FATIGUE (Mild fatigue and no interference with activity) in a patient of an unknown age and gender who received mRNA-1273.815 (SPIKEVAX 2023-2024) for COVID-19 prophylaxis.     No Medical History information was reported.    In December 2023, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form. In December 2023, the patient experienced MALAISE (Mild malaise/feeling sick and no interference with activity), VACCINATION SITE PAIN (Moderate injection site pain interfering with activity/Moderate injection site tenderness (tenderness with movement)), VACCINATION SITE ERYTHEMA (Mild injection site redness) and FATIGUE (Mild fatigue and no interference with activity). At the time of the report, MALAISE (Mild malaise/feeling sick and no interference with activity), VACCINATION SITE PAIN (Moderate injection site pain interfering with activity/Moderate injection site tenderness (tenderness with movement)), VACCINATION SITE ERYTHEMA (Mild injection site redness) and FATIGUE (Mild fatigue and no interference with activity) outcome was unknown.        The action taken with mRNA-1273.815 (SPIKEVAX 2023-2024) (Unknown) was unknown.       No concomitant medication was reported.  Patient had experienced events anytime during the 2 days after your COVID-19 vaccination, which occurred on Saturday, Dec 23, 2023 and Sunday, Dec 24, 2023.  No treatment information was reported.   This case was linked to US-MODERNATX, INC.-MOD-2024-756004 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2024-756004:Same reporter
Sex: U
Vaccine: COVID19
Symptoms: Fatigue, Headache, Malaise, Myalgia, Vaccination site pain
Clinical narrative: Moderate malaise/feeling sick present with some interference with activity; Moderate injection site pain interfering with activity; Moderate fatigue with some interference with activity; Moderate muscle pain with some interference with activity; Headache and no interference with activity; This spontaneous case was reported by a non-health professional and describes the occurrence of MALAISE (Moderate malaise/feeling sick present with some interference with activity), VACCINATION SITE PAIN (Moderate injection site pain interfering with activity), FATIGUE (Moderate fatigue with some interference with activity), MYALGIA (Moderate muscle pain with some interference with activity) and HEADACHE (Headache and no interference with activity) in a patient of an unknown age and gender who received mRNA-1273.815 (SPIKEVAX 2023-2024) for COVID-19 prophylaxis.     No Medical History information was reported.    In December 2023, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form. In December 2023, the patient experienced MALAISE (Moderate malaise/feeling sick present with some interference with activity), VACCINATION SITE PAIN (Moderate injection site pain interfering with activity), FATIGUE (Moderate fatigue with some interference with activity), MYALGIA (Moderate muscle pain with some interference with activity) and HEADACHE (Headache and no interference with activity). At the time of the report, MALAISE (Moderate malaise/feeling sick present with some interference with activity), VACCINATION SITE PAIN (Moderate injection site pain interfering with activity), FATIGUE (Moderate fatigue with some interference with activity), MYALGIA (Moderate muscle pain with some interference with activity) and HEADACHE (Headache and no interference with activity) outcome was unknown.        The action taken with mRNA-1273.815 (SPIKEVAX 2023-2024) (Unknown) was unknown.       No concomitant medication was reported.  Patient had experienced events anytime during the 2 days after your COVID-19 vaccination, which occurred on Saturday, Dec 23, 2023 and Sunday, Dec 24, 2023.  No treatment information was reported.   This case was linked to US-MODERNATX, INC.-MOD-2024-756004 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2024-756004:Same reporter
Sex: U
Vaccine: COVID19
Symptoms: Body temperature, Myalgia, Vaccination site pain
Clinical narrative: Mild injection site tenderness (tender to touch); Mild muscle pain and no interference with activity; This spontaneous case was reported by a non-healthcare professional and describes the occurrence of VACCINATION SITE PAIN (Mild injection site tenderness (tender to touch)) and MYALGIA (Mild muscle pain and no interference with activity) in a  patient of an unknown age and gender who received mRNA-1273.815 (SPIKEVAX 2023-2024) for COVID-19 prophylaxis.     No Medical History information was reported.    In December 2023, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form. In December 2023, the patient experienced VACCINATION SITE PAIN (Mild injection site tenderness (tender to touch)) and MYALGIA (Mild muscle pain and no interference with activity). At the time of the report, VACCINATION SITE PAIN (Mild injection site tenderness (tender to touch)) and MYALGIA (Mild muscle pain and no interference with activity) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In December 2023, Body temperature: less than 100.4 degree F.         No concomitant medications were reported.  Injection site tenderness and Muscle pain: Record worst tenderness experienced anytime during the 2 days after your COVID-19 vaccination, which occurred on Friday, Dec 22, 2023 and Saturday, Dec 23, 2023.  No treatment medications were reported.   This case was linked to US-MODERNATX, INC.-MOD-2024-756004 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2024-756004:Same reporter
Sex: U
Vaccine: COVID19
Symptoms: Fatigue, Headache, Myalgia, Vaccination site pain
Clinical narrative: Mild injection site pain and no interference with activity/Mild injection site tenderness (tender to touch); Mild fatigue and no interference with activity; Mild muscle pain and no interference with activity; Headache and no interference with activity; This spontaneous case was reported by a non-health professional and describes the occurrence of VACCINATION SITE PAIN (Mild injection site pain and no interference with activity/Mild injection site tenderness (tender to touch)), FATIGUE (Mild fatigue and no interference with activity), MYALGIA (Mild muscle pain and no interference with activity) and HEADACHE (Headache and no interference with activity) in a patient of an unknown age and gender who received mRNA-1273.815 (SPIKEVAX 2023-2024) for COVID-19 prophylaxis.     No Medical History information was reported.    In December 2023, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form. In December 2023, the patient experienced VACCINATION SITE PAIN (Mild injection site pain and no interference with activity/Mild injection site tenderness (tender to touch)), FATIGUE (Mild fatigue and no interference with activity), MYALGIA (Mild muscle pain and no interference with activity) and HEADACHE (Headache and no interference with activity). At the time of the report, VACCINATION SITE PAIN (Mild injection site pain and no interference with activity/Mild injection site tenderness (tender to touch)), FATIGUE (Mild fatigue and no interference with activity), MYALGIA (Mild muscle pain and no interference with activity) and HEADACHE (Headache and no interference with activity) outcome was unknown.        The action taken with mRNA-1273.815 (SPIKEVAX 2023-2024) (Unknown) was unknown.       No concomitant medications were reported.  It was reported that the patient experienced the events anytime during the 2 days after the COVID-19 vaccination, which occurred on Saturday, Dec 23, 2023 and Sunday, Dec 24, 2023.   No treatment medications were reported.   This case was linked to US-MODERNATX, INC.-MOD-2024-756004 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2024-756004:Same reporter
Sex: U
Vaccine: COVID19
Symptoms: Fatigue, Vaccination site pain, Vaccination site swelling
Clinical narrative: Mild injection site pain and no interference with activity/Mild injection site tenderness (tender to touch); Mild injection site swelling; Mild fatigue and no interference with activity; This spontaneous case was reported by a non-health professional and describes the occurrence of VACCINATION SITE PAIN (Mild injection site pain and no interference with activity/Mild injection site tenderness (tender to touch)), VACCINATION SITE SWELLING (Mild injection site swelling) and FATIGUE (Mild fatigue and no interference with activity) in a  patient of an unknown age and gender who received mRNA-1273.815 (SPIKEVAX 2023-2024) for COVID-19 prophylaxis.     No Medical History information was reported.    In December 2023, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form. In December 2023, the patient experienced VACCINATION SITE PAIN (Mild injection site pain and no interference with activity/Mild injection site tenderness (tender to touch)), VACCINATION SITE SWELLING (Mild injection site swelling) and FATIGUE (Mild fatigue and no interference with activity). At the time of the report, VACCINATION SITE PAIN (Mild injection site pain and no interference with activity/Mild injection site tenderness (tender to touch)), VACCINATION SITE SWELLING (Mild injection site swelling) and FATIGUE (Mild fatigue and no interference with activity) outcome was unknown.        The action taken with mRNA-1273.815 (SPIKEVAX 2023-2024) (Unknown) was unknown.       Concomitant medication was not reported.  Also, it has been reported that the symptom of malaise, vaccination site pain, vaccination site swelling, and fatigue were experienced anytime during the 2 days after vaccination on either Dec 20, 2023, or Dec 21, 2023. Further it has been reported that patient did not have symptoms of injection site redness, fever, Malaise or feeling sick, Muscle pain, Joint pain, nausea or vomiting and headache. No treatment medications provided by the reporter.   This case was linked to US-MODERNATX, INC.-MOD-2024-756004 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2024-756004:Same reporter
Sex: U
Vaccine: COVID19
Symptoms: Arthralgia, Body temperature, Myalgia, Vaccination site erythema, Vaccination site pain
Clinical narrative: 1-episodes of Mild injection site pain and no interference with activity; 1-episodes of Mild injection site redness; 1-episodes of Mild muscle pain and no interference with activity; 1-episodes of Joint pain and no interference with activity; This spontaneous case was reported by a non-healthcare professional and describes the occurrence of VACCINATION SITE PAIN (1-episodes of Mild injection site pain and no interference with activity), VACCINATION SITE ERYTHEMA (1-episodes of Mild injection site redness), MYALGIA (1-episodes of Mild muscle pain and no interference with activity) and ARTHRALGIA (1-episodes of Joint pain and no interference with activity) in a  patient of an unknown age and gender who received mRNA-1273.815 (SPIKEVAX 2023-2024) for COVID-19 prophylaxis.     No Medical History information was reported.    In December 2023, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form. In December 2023, the patient experienced VACCINATION SITE PAIN (1-episodes of Mild injection site pain and no interference with activity), VACCINATION SITE ERYTHEMA (1-episodes of Mild injection site redness), MYALGIA (1-episodes of Mild muscle pain and no interference with activity) and ARTHRALGIA (1-episodes of Joint pain and no interference with activity). At the time of the report, VACCINATION SITE PAIN (1-episodes of Mild injection site pain and no interference with activity), VACCINATION SITE ERYTHEMA (1-episodes of Mild injection site redness), MYALGIA (1-episodes of Mild muscle pain and no interference with activity) and ARTHRALGIA (1-episodes of Joint pain and no interference with activity) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In December 2023, Body temperature: No fever (< 100.4 °F).         Concomitant medication was not reported.  Also, it has been reported that the symptom of vaccination site pain, vaccination site erythema, myalgia and arthralgia (were experienced anytime during the 2 days after vaccination on either Dec 24, 2023, or Monday, Dec 25, 2023. Further it has been reported that patient did not have symptoms of tenderness at injection site, injection site swelling, fever, Fatigue, Malaise or feeling sick, nausea or vomiting and headache. No treatment medications provided by the reporter.   This case was linked to US-MODERNATX, INC.-MOD-2024-756004 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2024-756004:Same reporter
Sex: U
Vaccine: COVID19
Symptoms: Myalgia, Vaccination site erythema, Vaccination site pain, Vaccination site swelling
Clinical narrative: Mild injection site pain and no interference with activity/mild injection site tenderness (tender to touch); Mild injection site redness; Mild injection site swelling; Mild muscle pain and no interference with activity; This spontaneous case was reported by a non-health professional and describes the occurrence of VACCINATION SITE PAIN (Mild injection site pain and no interference with activity/mild injection site tenderness (tender to touch)), VACCINATION SITE ERYTHEMA (Mild injection site redness), VACCINATION SITE SWELLING (Mild injection site swelling) and MYALGIA (Mild muscle pain and no interference with activity) in a patient of an unknown age and gender who received mRNA-1273.815 (SPIKEVAX 2023-2024) for COVID-19 prophylaxis.     No Medical History information was reported.    In December 2023, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form. In December 2023, the patient experienced VACCINATION SITE PAIN (Mild injection site pain and no interference with activity/mild injection site tenderness (tender to touch)), VACCINATION SITE ERYTHEMA (Mild injection site redness), VACCINATION SITE SWELLING (Mild injection site swelling) and MYALGIA (Mild muscle pain and no interference with activity). At the time of the report, VACCINATION SITE PAIN (Mild injection site pain and no interference with activity/mild injection site tenderness (tender to touch)), VACCINATION SITE ERYTHEMA (Mild injection site redness), VACCINATION SITE SWELLING (Mild injection site swelling) and MYALGIA (Mild muscle pain and no interference with activity) outcome was unknown.        The action taken with mRNA-1273.815 (SPIKEVAX 2023-2024) (Unknown) was unknown.       Patient had experienced mild injection site pain, tenderness (tender to touch), redness, swelling and mild muscle pain and no interference with activity anytime during the 2 days after COVID-19 vaccination, which occurred on Friday, December 22, 2023, and Saturday, December 23, 2023.  Concomitant medications were not reported.   No treatment medication was provided by the reporter.  The Subject ID was reported.  The Subject ID was reported.   This case was linked to US-MODERNATX, INC.-MOD-2024-756004 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2024-756004:Same reporter
Sex: U
Vaccine: COVID19
Symptoms: Fatigue, Malaise, Myalgia, Vaccination site erythema, Vaccination site pain
Clinical narrative: Mild malaise/feeling sick and no interference with activity; Mild injection site pain and no interference with activity/ mild injection site tenderness (tender to touch); Mild injection site redness; Mild fatigue and no interference with activity; Moderate muscle pain with some interference with activity; This spontaneous case was reported by a non-health professional and describes the occurrence of MALAISE (Mild malaise/feeling sick and no interference with activity), VACCINATION SITE PAIN (Mild injection site pain and no interference with activity/ mild injection site tenderness (tender to touch)), VACCINATION SITE ERYTHEMA (Mild injection site redness), FATIGUE (Mild fatigue and no interference with activity) and MYALGIA (Moderate muscle pain with some interference with activity) in a patient of an unknown age and gender who received mRNA-1273.815 (SPIKEVAX 2023-2024) for COVID-19 prophylaxis.     No Medical History information was reported.    In December 2023, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form. In December 2023, the patient experienced MALAISE (Mild malaise/feeling sick and no interference with activity), VACCINATION SITE PAIN (Mild injection site pain and no interference with activity/ mild injection site tenderness (tender to touch)), VACCINATION SITE ERYTHEMA (Mild injection site redness), FATIGUE (Mild fatigue and no interference with activity) and MYALGIA (Moderate muscle pain with some interference with activity). At the time of the report, MALAISE (Mild malaise/feeling sick and no interference with activity), VACCINATION SITE PAIN (Mild injection site pain and no interference with activity/ mild injection site tenderness (tender to touch)), VACCINATION SITE ERYTHEMA (Mild injection site redness), FATIGUE (Mild fatigue and no interference with activity) and MYALGIA (Moderate muscle pain with some interference with activity) outcome was unknown.        The action taken with mRNA-1273.815 (SPIKEVAX 2023-2024) (Unknown) was unknown.       Patient had experienced mild injection site pain, tenderness (tender to touch), redness, fatigue, malaise with no interference with activity and moderate muscle pain with some interference with activity anytime during the 2 days after COVID-19 vaccination, which occurred on Thursday, December 21, 2023 and Friday, December 22, 2023.  Concomitant medications were not reported.   No treatment medication was provided by the reporter.  The AutoCruitment Subject ID was reported.  The RTI-HS Subject ID was reported.   This case was linked to US-MODERNATX, INC.-MOD-2024-756004 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2024-756004:same reporter
Sex: U
Vaccine: COVID19
Symptoms: Arthralgia, Body temperature, Myalgia, Pyrexia, Vaccination site erythema
Clinical narrative: Mild injection site pain and no interference with activity; Mild injection site redness; Mild injection site swelling; Mild fever (100.4 to 101.2 °F); Mild muscle pain and no interference with activity; Joint pain and no interference with activity; This spontaneous case was reported by a non-health professional and describes the occurrence of VACCINATION SITE PAIN (Mild injection site pain and no interference with activity), VACCINATION SITE ERYTHEMA (Mild injection site redness), VACCINATION SITE SWELLING (Mild injection site swelling), PYREXIA (Mild fever (100.4 to 101.2 °F)) and MYALGIA (Mild muscle pain and no interference with activity) in a patient of an unknown age and gender who received mRNA-1273.815 (SPIKEVAX 2023-2024) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    In December 2023, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form. In December 2023, the patient experienced VACCINATION SITE PAIN (Mild injection site pain and no interference with activity), VACCINATION SITE ERYTHEMA (Mild injection site redness), VACCINATION SITE SWELLING (Mild injection site swelling), PYREXIA (Mild fever (100.4 to 101.2 °F)), MYALGIA (Mild muscle pain and no interference with activity) and ARTHRALGIA (Joint pain and no interference with activity). At the time of the report, VACCINATION SITE PAIN (Mild injection site pain and no interference with activity), VACCINATION SITE ERYTHEMA (Mild injection site redness), VACCINATION SITE SWELLING (Mild injection site swelling), PYREXIA (Mild fever (100.4 to 101.2 °F)), MYALGIA (Mild muscle pain and no interference with activity) and ARTHRALGIA (Joint pain and no interference with activity) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In December 2023, Body temperature: Mild fever (100.4 to 101.2 °F).     The action taken with mRNA-1273.815 (SPIKEVAX 2023-2024) (Unknown) was unknown.       Concomitant medications were not reported.   Patient had experienced the events anytime during the 2 days after the COVID-19 vaccination, which occurred on Friday, Dec 22, 2023 and Saturday, Dec 23, 2023.  No treatment information was provided by the reporter.   This case was linked to US-MODERNATX, INC.-MOD-2024-756004 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2024-756004:Same reporter
Sex: U
Vaccine: COVID19
Symptoms: Vaccination site pain, Vaccination site swelling
Clinical narrative: Mild injection site pain and no interference with activity; Mild injection site redness; Mild injection site swelling; Mild fever (100.4 to 101.2 °F); Mild muscle pain and no interference with activity; Joint pain and no interference with activity; This spontaneous case was reported by a non-health professional and describes the occurrence of VACCINATION SITE PAIN (Mild injection site pain and no interference with activity), VACCINATION SITE ERYTHEMA (Mild injection site redness), VACCINATION SITE SWELLING (Mild injection site swelling), PYREXIA (Mild fever (100.4 to 101.2 °F)) and MYALGIA (Mild muscle pain and no interference with activity) in a patient of an unknown age and gender who received mRNA-1273.815 (SPIKEVAX 2023-2024) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    In December 2023, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form. In December 2023, the patient experienced VACCINATION SITE PAIN (Mild injection site pain and no interference with activity), VACCINATION SITE ERYTHEMA (Mild injection site redness), VACCINATION SITE SWELLING (Mild injection site swelling), PYREXIA (Mild fever (100.4 to 101.2 °F)), MYALGIA (Mild muscle pain and no interference with activity) and ARTHRALGIA (Joint pain and no interference with activity). At the time of the report, VACCINATION SITE PAIN (Mild injection site pain and no interference with activity), VACCINATION SITE ERYTHEMA (Mild injection site redness), VACCINATION SITE SWELLING (Mild injection site swelling), PYREXIA (Mild fever (100.4 to 101.2 °F)), MYALGIA (Mild muscle pain and no interference with activity) and ARTHRALGIA (Joint pain and no interference with activity) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In December 2023, Body temperature: Mild fever (100.4 to 101.2 °F).     The action taken with mRNA-1273.815 (SPIKEVAX 2023-2024) (Unknown) was unknown.       Concomitant medications were not reported.   Patient had experienced the events anytime during the 2 days after the COVID-19 vaccination, which occurred on Friday, Dec 22, 2023 and Saturday, Dec 23, 2023.  No treatment information was provided by the reporter.   This case was linked to US-MODERNATX, INC.-MOD-2024-756004 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2024-756004:Same reporter
Sex: U
Vaccine: COVID19
Symptoms: Vaccination site pain
Clinical narrative: Mild injection site pain and no interference with activity/ Mild injection site tenderness (tender to touch); This spontaneous case was reported by a non-health professional and describes the occurrence of VACCINATION SITE PAIN (Mild injection site pain and no interference with activity/ Mild injection site tenderness (tender to touch)) in a patient of an unknown age and gender who received mRNA-1273.815 (SPIKEVAX 2023-2024) for COVID-19 prophylaxis.     No Medical History information was reported.    In December 2023, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form. In December 2023, the patient experienced VACCINATION SITE PAIN (Mild injection site pain and no interference with activity/ Mild injection site tenderness (tender to touch)). At the time of the report, VACCINATION SITE PAIN (Mild injection site pain and no interference with activity/ Mild injection site tenderness (tender to touch)) outcome was unknown.        The action taken with mRNA-1273.815 (SPIKEVAX 2023-2024) (Unknown) was unknown.       Patient had experienced vaccination site pain anytime during the 2 days after your COVID-19 vaccination, which occurred on Friday, Dec 22, 2023 and Saturday, Dec 23, 2023. Concomitant medications were not reported.  No treatment information was provided by the reporter.   This case was linked to US-MODERNATX, INC.-MOD-2024-756004 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2024-756004:same reporter